In a phase 1b study, the addition of the oral MEK inhibitor binimetinib to the treatment combination of cisplatin and pemetrexed as first-line therapy in advanced KRAS-mutated metastatic NSCLC showed no signal of anti-tumor activity in terms of PFS or OS. Here, KRAS is linked to non-small cell lung carcinoma.